Biosimilars Are Here. Now What?

More and more biosimilars enter the market raising questions around pricing, regulations, but also how to convince physicians to start using biosimilars, and how to switch the patients.

This is an excerpt from a panel discussion with Jim Roach of Momenta Pharmaceuticals, Inc., Irena Royzman of Patterson Belknap Webb & Tyler LLP, Sophie Opdyke of  Pfizer, Chrys Kokino of Mylan, and was moderated by John Farah of Red Team Associates. This panel of experts shed light on the following topics:

  1. The benefits and risks associated with bringing biosimilars into the U.S. market.
  2. What do we need to do to accelerate the timeframe of how we accept biosimilars in the U.S.?
  3. Because of the high costs, how do we increase support to get these products into the country?

View the complete discussion.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s